Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% – Here’s Why

Repare Therapeutics Inc. (NASDAQ:RPTX)’s stock price rose 0.4% on Wednesday . The stock traded as high as $2.61 and last traded at $2.60. Approximately 426,036 shares changed hands during trading, a decline of 71% from the average daily volume of 1,465,188 shares. The stock had previously closed at $2.59.

Analyst Upgrades and Downgrades

RPTX has been the subject of a number of research analyst reports. HC Wainwright reduced their price target on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Cowen lowered shares of Repare Therapeutics to a “hold” rating in a research note on Monday, November 17th. Wall Street Zen raised shares of Repare Therapeutics to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a research note on Monday, December 22nd. Finally, TD Cowen downgraded Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Repare Therapeutics Trading Up 0.4%

The stock has a fifty day simple moving average of $2.23 and a 200-day simple moving average of $1.86. The stock has a market cap of $112.09 million, a price-to-earnings ratio of -1.54 and a beta of 0.97.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings results on Friday, November 14th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.43. The company had revenue of $11.62 million during the quarter, compared to the consensus estimate of $7.50 million. Sell-side analysts forecast that Repare Therapeutics Inc. will post -2.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repare Therapeutics

Hedge funds have recently made changes to their positions in the business. Rangeley Capital LLC acquired a new position in shares of Repare Therapeutics in the 2nd quarter worth approximately $494,000. Acadian Asset Management LLC lifted its position in Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock valued at $624,000 after purchasing an additional 168,230 shares during the period. Militia Capital Partners LP acquired a new position in Repare Therapeutics in the second quarter valued at approximately $166,000. Squarepoint Ops LLC bought a new position in shares of Repare Therapeutics in the 3rd quarter worth $115,000. Finally, XTX Topco Ltd acquired a new position in shares of Repare Therapeutics during the 2nd quarter worth about $60,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.